No room for 'biased' patients and doctors in Germany's AMNOG system
This article was originally published in Scrip
Patient organizations and medical societies are not impartial enough and lack the expertise to have any greater involvement in Germany's AMNOG pricing and reimbursement system, said Josef Hecken, head of the G-BA, the committee in charge of the AMNOG process.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.